Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: A systematic review and meta-analysis

JAMA Internal Medicine

Volumn 176, Issue 4, 2016, Pages 453-462

  Jaspers, Loes ^a   Feys, Frederik ^b   Bramer, Wichor M ^a   Franco, Oscar H ^a   Leusink, Peter ^c   Laan, Ellen T M ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c GROENE HART HOSPITAL   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLIBANSERIN; PLACEBO; BENZIMIDAZOLE DERIVATIVE;

APPENDICITIS; BEDTIME DOSAGE; CHOLELITHIASIS; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; COMMON COLD; CONCUSSION; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FAINTNESS; FATIGUE; FEMALE; FEMALE SEXUAL FUNCTION INDEX; FOOD AND DRUG ADMINISTRATION; HETEROSEXUALITY; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; HYPOTENSION; INJURY; LENGTH OF STAY; META ANALYSIS; MONOGAMY; NAUSEA; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL SATISFACTION; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; CHEMICALLY INDUCED; LIBIDO; PATIENT SATISFACTION; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME;

BENZIMIDAZOLES; DIZZINESS; FATIGUE; FEMALE; HUMANS; LIBIDO; NAUSEA; PATIENT SATISFACTION; PREMENOPAUSE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 84962757777     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.8565     Document Type: Review

References (37)

1. US Food and Drug Administration. FDA news release: FDA approves first treatment for sexual desire disorder. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm458734.htm. Accessed September 10, 2015.
2. Popova NK, Amstislavskaya TG. Involvement of the 5-HT(1A) and 5-HT(1B) serotonergic receptor subtypes in sexual arousal in malemice. Psychoneuroendocrinology. 2002;27(5):609-618.
3. Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011;8(1):15-27.
4. Pfaus JG. Pathways of sexual desire. J Sex Med. 2009;6(6):1506-1533.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision.Washington, DC: American Psychiatric Association; 2000.
6. Dennerstein L, Hayes RD. Confronting the challenges: epidemiological study of female sexual dysfunction and the menopause. J Sex Med. 2005;2 (suppl 3):118-132.
7. GelladWF, Flynn KE, Alexander GC. Evaluation of flibanserin: science and advocacy at the FDA. JAMA. 2015;314(9):869-870.
8. Thorp J Jr, Palacios S, Symons J, Simon J, Barbour K. Improving prospects for treating hypoactive sexual desire disorder (HSDD): development status of flibanserin. BJOG. 2014;121 (11):1328-1331.
9. Schulte B, Dennis B. FDA approves controversial drug for women with low sex drives. TheWashington Post, 2015. http://www.washingtonpost.com/national/health-science/fda-approves-controversial-female-viagra-drug/2015/08/18/68d34eca-45f6-11e5-8e7d-9c033e6745d8-story.html. Accessed August 29, 2015.
10. Clayton AH, Dennerstein L, Pyke R, Sand M. Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women. Womens Health (Lond Engl). 2010;6(5):639-653.
11. Frühauf S, Gerger H, Schmidt HM, Munder T, Barth J. Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav. 2013;42(6):915-933.
12. Kingsberg SA, Rezaee RL. Hypoactive sexual desire in women. Menopause. 2013;20(12): 1284-1300.
13. Lodise NM. Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health. Pharmacotherapy. 2013;33(4):411-421.
14. Moynihan R. Evening the score on sex drugs: feministmovement or marketingmasquerade? BMJ. 2014;349:g6246.
15. Palacios S. Hypoactive Sexual Desire Disorder and current pharmacotherapeutic options in women.Womens Health (Lond Engl). 2011;7(1): 95-107.
16. Reviriego C. Flibanserin for female sexual dysfunction. Drugs Today (Barc). 2014;50(8): 549-556.
17. Wylie K, Daines B, Jannini EA, et al. Loss of sexual desire in the postmenopausal woman. J Sex Med. 2007;4(2):395-405.
18. Sprout Pharmaceuticals. Flibanserin for the treatment of Hypoactive Sexual Desire Disorder in PremenopausalWomen: NDA 022526: Advisory Committee Briefing Document. June 4, 2015. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/drugsafetyandriskmanagementadvisorycommittee/ucm449090.pdf. Accessed September 6, 2015.
19. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. http://www.cochrane-handbook.org. Accessed September 6, 2015.
20. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2): 191-208.
21. Derogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med. 2008;5(2):357-364.
22. Bradford A. Listening to placebo in clinical trials for female sexual dysfunction. J Sex Med. 2013;10 (2):451-459.
23. Feys F, Bekkering GE, Singh K, Devroey D. Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups? a protocol for ameta-epidemiological study of PDE-5 inhibitors. Syst Rev. 2012;1:54.
24. Derogatis LR, Komer L, Katz M, et al; VIOLET Trial Investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med. 2012; 9(4):1074-1085.
25. Goldfischer ER, Breaux J, Katz M, et al. Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial. J Sex Med. 2011;8(11):3160-3172.
26. KatzM, DeRogatis LR, Ackerman R, et al; BEGONIA trial investigators. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10 (7):1807-1815.
27. Simon JA, Kingsberg SA, Shumel B, Hanes V, GarciaMJr, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21(6):633-640.
28. Thorp J, Simon J, Dattani D, et al; DAISY trial investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012;9 (3):793-804.
29. US Food and Drug Administration. What is a serious adverse event? http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm. Accessed September 10, 2015.
30. Jakobsen JC,Wetterslev J,Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med ResMethodol. 2014;14:120.
31. Nijland E, Davis S, Laan E, SchultzWW. Female sexual satisfaction and pharmaceutical intervention: a critical review of the drug intervention studies in female sexual dysfunction. J Sex Med. 2006;3(5):763-777.
32. Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J. The thresholds for statistical and clinical significance: a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Med ResMethodol. 2014;14:34.
33. US Food and Drug Administration. FDA Briefing Document: Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee. June 5, 2015. NDA 022526. Flibanserin. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisory Committee/UCM449088.pdf. Accessed November 3, 2015.
34. Symonds T, Spino C, Sisson M, et al.Methods to determine the minimum important difference for a sexual event diary used by postmenopausal women with hypoactive sexual desire disorder. J Sex Med. 2007;4(5):1328-1335.
35. Jayne C, Simon JA, Taylor LV, Kimura T, Lesko LM; SUNFLOWER Study Investigators. Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med. 2012;9(12):3180-3188.
36. Brotto LA. Flibanserin. Arch Sex Behav. 2015;44 (8):2103-2105.
37. Snabes MC, Simes SM. Approved hormonal treatments for HSDD: an unmet medical need. J Sex Med. 2009;6(7):1846-1849.